GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Liver Transplantation/Living-Donor Liver Transplantation Improves Survival in Unresectable Colorectal Liver Metastases : Liver Transpl | May 2026

Living-Donor Liver Transplantation Improves Survival in Unresectable Colorectal Liver Metastases : Liver Transpl | May 2026

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated May 1, 2026

Quick Answer

Introduction Colorectal liver metastases remain a major cause of cancer-related mortality, and curative treatment is traditionally limited to patients eligible for hepatic resection. However, many patients present with technically unresectable liver-only disease despite favorable tumor biology and good response to systemic chemotherapy.


Introduction

Colorectal liver metastases remain a major cause of cancer-related mortality, and curative treatment is traditionally limited to patients eligible for hepatic resection. However, many patients present with technically unresectable liver-only disease despite favorable tumor biology and good response to systemic chemotherapy. In recent years, liver transplantation has re-emerged as a potential treatment strategy for carefully selected patients with unresectable colorectal liver metastases.

Problem Statement

Although promising survival outcomes have been reported with liver transplantation in selected metastatic colorectal cancer patients, widespread adoption remains limited by donor organ scarcity, concerns regarding recurrence and uncertainty regarding long-term oncologic benefit compared with modern systemic therapy alone.

Summary

This study demonstrates that liver transplantation using a living-donor RAPID approach provides a substantial survival advantage over chemotherapy alone in carefully selected patients with unresectable colorectal liver metastases. Eligible patients had liver-confined disease with stable disease or tumor regression following systemic therapy, reflecting strict biologic selection criteria. Patients undergoing transplantation achieved markedly superior long-term survival compared with patients who could not proceed because of donor unavailability, supporting transplantation as a potentially curative strategy in highly selected metastatic colorectal cancer. The RAPID technique, involving staged partial liver transplantation with delayed hepatectomy, also highlights an innovative approach to expanding transplant feasibility while minimizing donor burden. Although recurrence remained common after transplantation, recurrent disease was often compatible with prolonged post-recurrence survival, suggesting that transplantation may meaningfully alter disease trajectory even when recurrence occurs. Importantly, the study reinforces the growing concept that tumor biology and treatment responsiveness may be more relevant than traditional metastatic classification alone when considering advanced surgical or transplant-based oncologic strategies. Overall, these findings strengthen the evolving role of liver transplantation in transplant oncology and support living-donor transplantation as a feasible pathway to expand access for selected patients with unresectable colorectal liver metastases.

Related Q&A

Synbiotics After Liver Transplant Show No Clinical Benefit: Liver Transplant | July 2026

Introduction: Bacterial infections remain a major cause of morbidity after liver transplantation despite advances in perioperative care. Synbiotics, combining probiotics and prebiotics, have been proposed to reduce postoperative infections by restoring gut microbiota and strengthening...

Tranexamic Acid in Liver Transplantation: Liver Transplant | June 2026

Introduction: Perioperative bleeding remains a major challenge during orthotopic liver transplantation (OLT), largely due to hyperfibrinolysis and coagulation abnormalities. Although tranexamic acid (TXA) effectively reduces bleeding in several surgical settings, its routine prophylactic use during...

Whole-Organ Donor Liver Assessment Using PS-OCT: Science Translational Medicine | July 2026

Introduction: Liver transplantation is limited by a shortage of suitable donor organs. Current viability assessment relies on needle biopsy, which samples only a small portion of the liver and may miss important regional pathology. This...

Personalizing Antifibrinolytic Use in Liver Transplantation : Liver Transpl | Jul 2026

Introduction: Bleeding remains a major challenge during liver transplantation despite advances in surgical techniques, anesthesia, and perioperative care. Antifibrinolytic agents have long been used to reduce intraoperative blood loss and transfusion requirements. However, evolving transplant...

Integrating LDLT into Modern Liver Transplant Programs: Liver Transplantation | June 2026

Introduction: The demand for liver transplantation continues to exceed the availability of deceased donor organs, resulting in prolonged waiting times and preventable waitlist mortality. This perspective discusses how living donor liver transplantation (LDLT) can complement...

Post-Transplant Management in Pediatric LT: Liver Transplantation | June 2026

Introduction: Pediatric liver transplantation has achieved excellent survival rates, shifting the focus from graft survival alone to optimising long-term health, growth, neurodevelopment, and quality of life. This updated guideline provides evidence-based recommendations for comprehensive care...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer